利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.018 秒)

    ANTICANCER AGENT COMPOSITION
    2.
    发明公开
    ANTICANCER AGENT COMPOSITION 审中-公开
    ZUSAMMENSETZUNGFÜRANTIKREBSMITTEL

    公开(公告)号：EP3100742A4

    公开(公告)日：2017-10-04

    申请号：EP15743649

    申请日：2015-01-26

    申请人： CARNA BIOSCIENCES INC

    发明人： FUNAKOSHI YOKO ,  TANAKA CHIKA ,  ASAMI TOKIKO ,  SAWA MASAAKI

    IPC分类号： A61K45/06 ,  A61K31/395 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/553 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

    CPC分类号： A61K31/553 ,  A61K31/395 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    摘要： Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is -COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom. However, if A is -COOR1, R2 and R3 are not both simultaneously optionally substituted amino groups. When A is a hydrogen atom, R3 is a hydrogen atom.)

    摘要翻译： 提供了包含Cdc7抑制剂和M相促进剂的药物组合物。 特别地，药物组合物中含有的Cdc7抑制剂是由式（I）表示的呋喃酮衍生物或其药学上可接受的盐。 （式中，A是-COOR 1或氢原子; R 1是氢原子，任选取代的烃基或任选取代的杂环; R 2和R 3相同或不同并且各自是氢原子，任选取代的 烃基，任选取代的苯基，任选取代的杂环，任选取代的杂环稠合环或任选取代的氨基，或者，R 2和R 3可以与连接它们的氮原子一起形成任选取代的杂环或 任选取代的杂环稠合环，R 4为氢原子或卤素原子，但若A为-COOR 1，则R 2和R 3不能同时为任意取代的氨基，A为氢原子时，R 3为氢原子。

    NOVEL TRIAZINE DERIVATIVE
    3.
    发明公开
    NOVEL TRIAZINE DERIVATIVE 审中-公开
    NEUARTIGES TRIAZINDERIVAT

    公开(公告)号：EP3026050A4

    公开(公告)日：2016-12-14

    申请号：EP14828654

    申请日：2014-07-15

    申请人： CARNA BIOSCIENCES INC

    发明人： KAWAHATA WATARU ,  ASAMI TOKIKO ,  SAWA MASAAKI ,  ASAMITSU YUKO ,  IRIE TAKAYUKI ,  MIYAKE TAKAHIRO ,  KIYOI TAKAO

    IPC分类号： C07D401/14 ,  A61K31/53 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/08

    CPC分类号： C07D401/14 ,  A61K31/53 ,  C07D403/14

    摘要： The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R 1 represents a substituted or unsubstituted lower alkyl group, R 2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C-R 3 , R 3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R 4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明的目的是提供一种新的式（I）三嗪衍生物：其中R 1表示取代或未取代的低级烷基，R 2表示氢原子或取代或未取代的低级烷基，A表示 氮原子或CR 3，R 3表示氢原子，氰基，取代或未取代的酰基，取代或未取代的磺酰基或取代或未取代的氨基甲酰基，R 4表示取代或未取代的低级烷基 ，或取代或未取代的环烷基，或其药学上可接受的盐。

    NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE
    6.
    发明公开
    NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE 审中-公开
    中和剂2,6-二氨基嘧啶衍生物

    公开(公告)号：EP3042899A1

    公开(公告)日：2016-07-13

    申请号：EP14842654.7

    申请日：2014-09-01

    申请人： Carna Biosciences, Inc.

    发明人： KAWAHATA, Wataru ,  ASAMI, Tokiko ,  SAWA, Masaaki ,  IRIE, Takayuki

    IPC分类号： C07D401/10 ,  C07D401/14 ,  A61K31/506 ,  A61K31/5377 ,  A61P19/08 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

    CPC分类号： C07D403/14 ,  C07D401/10 ,  C07D401/14

    摘要： To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I):
    A 2,6-diaminopyrimidine derivative is represented by the formula (I):

    wherein
    R 1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,
    Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group,
    Z 1 and Z 2 represent carbon atoms, or either 1 or 2 of the Z 1 and Z 2 represent nitrogen atoms,
    Q is selected from a structure (a) or (b) described below:

    R 2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group,
    R 3 represents a hydrogen atom or a halogen atom,
    Y represents a nitrogen atom or a carbon atom, and
    the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.

    摘要翻译： 通过下式（I）提供新的2,6-二氨基嘧啶衍生物：2,6-二氨基嘧啶衍生物由式（I）表示：其中R 1表示取代或未取代的低级烷基，或取代或未取代的 未取代的烷氧基，Ar表示取代或未取代的芳基或取代或未取代的杂芳基，Z 1和Z 2表示碳原子，或者1或2的Z 1和Z 2表示氮原子，Q选自 下述结构（a）或（b）：R 2表示取代或未取代的低级烷基或取代或未取代的环烷基，R 3表示氢原子或卤素原子，Y表示氮原子或碳 原子，并且用结构（a）上平行于实线的虚线绘制的键表示双键或单键。